AAVantgarde Bio

AAVantgarde is a clinical-stage, Italy-based international biotechechnology company with a clear mission: unlocking the full potential of AAV gene therapy.

The company is validating two proprietary platforms in inherited retinal diseases — and the underlying technology, which overcomes AAV's longstanding transgene capacity limits to deliver large genes to tissue and cells in vivo, has implications well beyond the eye.

AAVantgarde's mission is to retain and rejuvenate sight for patients with inherited retinal disorders (IRDs) through next-generation therapies.